

Global Biosimilars Insulin Market Growth 2025-2031

<https://marketpublishers.com/r/GE22CC326CBEEN.html>

Date: October 2025

Pages: 89

Price: US\$ 3,660.00 (Single User License)

ID: GE22CC326CBEEN

Abstracts

The global Biosimilars Insulin market size is predicted to grow from US\$ million in 2025 to US\$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called ?Insulin glargine? and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first ?biosimilar? insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.

Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine

Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi's basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.

LP Information, Inc. (LPI) ' newest research report, the "Biosimilars Insulin Industry Forecast" looks at past sales and reviews total world Biosimilars Insulin sales in 2024, providing a comprehensive analysis by region and market sector of projected Biosimilars Insulin sales for 2025 through 2031. With Biosimilars Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Biosimilars Insulin industry.

This Insight Report provides a comprehensive analysis of the global Biosimilars Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilars Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biosimilars Insulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilars Insulin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilars Insulin.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilars Insulin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Insulin Glargine

Insulin Aspart

Insulin Lispro

Other

Segmentation by Application:

Type I Diabetes

Type II Diabetes

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Boehringer Ingelheim

Biocon/Mylan

Gan & Lee Pharmaceuticals

Tonghua Dongbao

United Laboratories

Sanofi

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilars Insulin market?

What factors are driving Biosimilars Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilars Insulin market opportunities vary by end market size?

How does Biosimilars Insulin break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Biosimilars Insulin Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Biosimilars Insulin by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Biosimilars Insulin by Country/Region, 2020, 2024 & 2031
- 2.2 Biosimilars Insulin Segment by Type
 - 2.2.1 Insulin Glargine
 - 2.2.2 Insulin Aspart
 - 2.2.3 Insulin Lispro
 - 2.2.4 Other
- 2.3 Biosimilars Insulin Sales by Type
 - 2.3.1 Global Biosimilars Insulin Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Biosimilars Insulin Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Biosimilars Insulin Sale Price by Type (2020-2025)
- 2.4 Biosimilars Insulin Segment by Application
 - 2.4.1 Type I Diabetes
 - 2.4.2 Type II Diabetes
- 2.5 Biosimilars Insulin Sales by Application
 - 2.5.1 Global Biosimilars Insulin Sale Market Share by Application (2020-2025)
 - 2.5.2 Global Biosimilars Insulin Revenue and Market Share by Application (2020-2025)
 - 2.5.3 Global Biosimilars Insulin Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

- 3.1 Global Biosimilars Insulin Breakdown Data by Company
 - 3.1.1 Global Biosimilars Insulin Annual Sales by Company (2020-2025)
 - 3.1.2 Global Biosimilars Insulin Sales Market Share by Company (2020-2025)
- 3.2 Global Biosimilars Insulin Annual Revenue by Company (2020-2025)
 - 3.2.1 Global Biosimilars Insulin Revenue by Company (2020-2025)
 - 3.2.2 Global Biosimilars Insulin Revenue Market Share by Company (2020-2025)
- 3.3 Global Biosimilars Insulin Sale Price by Company
- 3.4 Key Manufacturers Biosimilars Insulin Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Biosimilars Insulin Product Location Distribution
 - 3.4.2 Players Biosimilars Insulin Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BIOSIMILARS INSULIN BY GEOGRAPHIC REGION

- 4.1 World Historic Biosimilars Insulin Market Size by Geographic Region (2020-2025)
 - 4.1.1 Global Biosimilars Insulin Annual Sales by Geographic Region (2020-2025)
 - 4.1.2 Global Biosimilars Insulin Annual Revenue by Geographic Region (2020-2025)
- 4.2 World Historic Biosimilars Insulin Market Size by Country/Region (2020-2025)
 - 4.2.1 Global Biosimilars Insulin Annual Sales by Country/Region (2020-2025)
 - 4.2.2 Global Biosimilars Insulin Annual Revenue by Country/Region (2020-2025)
- 4.3 Americas Biosimilars Insulin Sales Growth
- 4.4 APAC Biosimilars Insulin Sales Growth
- 4.5 Europe Biosimilars Insulin Sales Growth
- 4.6 Middle East & Africa Biosimilars Insulin Sales Growth

5 AMERICAS

- 5.1 Americas Biosimilars Insulin Sales by Country
 - 5.1.1 Americas Biosimilars Insulin Sales by Country (2020-2025)
 - 5.1.2 Americas Biosimilars Insulin Revenue by Country (2020-2025)
- 5.2 Americas Biosimilars Insulin Sales by Type (2020-2025)
- 5.3 Americas Biosimilars Insulin Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Biosimilars Insulin Sales by Region

6.1.1 APAC Biosimilars Insulin Sales by Region (2020-2025)

6.1.2 APAC Biosimilars Insulin Revenue by Region (2020-2025)

6.2 APAC Biosimilars Insulin Sales by Type (2020-2025)

6.3 APAC Biosimilars Insulin Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Biosimilars Insulin by Country

7.1.1 Europe Biosimilars Insulin Sales by Country (2020-2025)

7.1.2 Europe Biosimilars Insulin Revenue by Country (2020-2025)

7.2 Europe Biosimilars Insulin Sales by Type (2020-2025)

7.3 Europe Biosimilars Insulin Sales by Application (2020-2025)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Biosimilars Insulin by Country

8.1.1 Middle East & Africa Biosimilars Insulin Sales by Country (2020-2025)

8.1.2 Middle East & Africa Biosimilars Insulin Revenue by Country (2020-2025)

8.2 Middle East & Africa Biosimilars Insulin Sales by Type (2020-2025)

8.3 Middle East & Africa Biosimilars Insulin Sales by Application (2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Biosimilars Insulin

10.3 Manufacturing Process Analysis of Biosimilars Insulin

10.4 Industry Chain Structure of Biosimilars Insulin

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Biosimilars Insulin Distributors

11.3 Biosimilars Insulin Customer

12 WORLD FORECAST REVIEW FOR BIOSIMILARS INSULIN BY GEOGRAPHIC REGION

12.1 Global Biosimilars Insulin Market Size Forecast by Region

12.1.1 Global Biosimilars Insulin Forecast by Region (2026-2031)

12.1.2 Global Biosimilars Insulin Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Biosimilars Insulin Forecast by Type (2026-2031)

12.7 Global Biosimilars Insulin Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly

13.1.1 Eli Lilly Company Information

13.1.2 Eli Lilly Biosimilars Insulin Product Portfolios and Specifications

13.1.3 Eli Lilly Biosimilars Insulin Sales, Revenue, Price and Gross Margin

(2020-2025)

13.1.4 Eli Lilly Main Business Overview

13.1.5 Eli Lilly Latest Developments

13.2 Boehringer Ingelheim

13.2.1 Boehringer Ingelheim Company Information

13.2.2 Boehringer Ingelheim Biosimilars Insulin Product Portfolios and Specifications

13.2.3 Boehringer Ingelheim Biosimilars Insulin Sales, Revenue, Price and Gross

Margin (2020-2025)

13.2.4 Boehringer Ingelheim Main Business Overview

13.2.5 Boehringer Ingelheim Latest Developments

13.3 Biocon/Mylan

13.3.1 Biocon/Mylan Company Information

13.3.2 Biocon/Mylan Biosimilars Insulin Product Portfolios and Specifications

13.3.3 Biocon/Mylan Biosimilars Insulin Sales, Revenue, Price and Gross Margin

(2020-2025)

13.3.4 Biocon/Mylan Main Business Overview

13.3.5 Biocon/Mylan Latest Developments

13.4 Gan & Lee Pharmaceuticals

13.4.1 Gan & Lee Pharmaceuticals Company Information

13.4.2 Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolios and

Specifications

13.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales, Revenue, Price and

Gross Margin (2020-2025)

13.4.4 Gan & Lee Pharmaceuticals Main Business Overview

13.4.5 Gan & Lee Pharmaceuticals Latest Developments

13.5 Tonghua Dongbao

13.5.1 Tonghua Dongbao Company Information

13.5.2 Tonghua Dongbao Biosimilars Insulin Product Portfolios and Specifications

13.5.3 Tonghua Dongbao Biosimilars Insulin Sales, Revenue, Price and Gross Margin

(2020-2025)

13.5.4 Tonghua Dongbao Main Business Overview

13.5.5 Tonghua Dongbao Latest Developments

13.6 United Laboratories

13.6.1 United Laboratories Company Information

13.6.2 United Laboratories Biosimilars Insulin Product Portfolios and Specifications

13.6.3 United Laboratories Biosimilars Insulin Sales, Revenue, Price and Gross

Margin (2020-2025)

13.6.4 United Laboratories Main Business Overview

13.6.5 United Laboratories Latest Developments

13.7 Sanofi

13.7.1 Sanofi Company Information

13.7.2 Sanofi Biosimilars Insulin Product Portfolios and Specifications

13.7.3 Sanofi Biosimilars Insulin Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 Sanofi Main Business Overview

13.7.5 Sanofi Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Biosimilars Insulin Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Table 2. Biosimilars Insulin Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)
- Table 3. Major Players of Insulin Glargine
- Table 4. Major Players of Insulin Aspart
- Table 5. Major Players of Insulin Lispro
- Table 6. Major Players of Other
- Table 7. Global Biosimilars Insulin Sales by Type (2020-2025) & (K Units)
- Table 8. Global Biosimilars Insulin Sales Market Share by Type (2020-2025)
- Table 9. Global Biosimilars Insulin Revenue by Type (2020-2025) & (\$ million)
- Table 10. Global Biosimilars Insulin Revenue Market Share by Type (2020-2025)
- Table 11. Global Biosimilars Insulin Sale Price by Type (2020-2025) & (USD/Unit)
- Table 12. Global Biosimilars Insulin Sale by Application (2020-2025) & (K Units)
- Table 13. Global Biosimilars Insulin Sale Market Share by Application (2020-2025)
- Table 14. Global Biosimilars Insulin Revenue by Application (2020-2025) & (\$ million)
- Table 15. Global Biosimilars Insulin Revenue Market Share by Application (2020-2025)
- Table 16. Global Biosimilars Insulin Sale Price by Application (2020-2025) & (USD/Unit)
- Table 17. Global Biosimilars Insulin Sales by Company (2020-2025) & (K Units)
- Table 18. Global Biosimilars Insulin Sales Market Share by Company (2020-2025)
- Table 19. Global Biosimilars Insulin Revenue by Company (2020-2025) & (\$ millions)
- Table 20. Global Biosimilars Insulin Revenue Market Share by Company (2020-2025)
- Table 21. Global Biosimilars Insulin Sale Price by Company (2020-2025) & (USD/Unit)
- Table 22. Key Manufacturers Biosimilars Insulin Producing Area Distribution and Sales Area
- Table 23. Players Biosimilars Insulin Products Offered
- Table 24. Biosimilars Insulin Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
- Table 25. New Products and Potential Entrants
- Table 26. Market M&A Activity & Strategy
- Table 27. Global Biosimilars Insulin Sales by Geographic Region (2020-2025) & (K Units)
- Table 28. Global Biosimilars Insulin Sales Market Share Geographic Region (2020-2025)
- Table 29. Global Biosimilars Insulin Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 30. Global Biosimilars Insulin Revenue Market Share by Geographic Region (2020-2025)

Table 31. Global Biosimilars Insulin Sales by Country/Region (2020-2025) & (K Units)

Table 32. Global Biosimilars Insulin Sales Market Share by Country/Region (2020-2025)

Table 33. Global Biosimilars Insulin Revenue by Country/Region (2020-2025) & (\$ millions)

Table 34. Global Biosimilars Insulin Revenue Market Share by Country/Region (2020-2025)

Table 35. Americas Biosimilars Insulin Sales by Country (2020-2025) & (K Units)

Table 36. Americas Biosimilars Insulin Sales Market Share by Country (2020-2025)

Table 37. Americas Biosimilars Insulin Revenue by Country (2020-2025) & (\$ millions)

Table 38. Americas Biosimilars Insulin Sales by Type (2020-2025) & (K Units)

Table 39. Americas Biosimilars Insulin Sales by Application (2020-2025) & (K Units)

Table 40. APAC Biosimilars Insulin Sales by Region (2020-2025) & (K Units)

Table 41. APAC Biosimilars Insulin Sales Market Share by Region (2020-2025)

Table 42. APAC Biosimilars Insulin Revenue by Region (2020-2025) & (\$ millions)

Table 43. APAC Biosimilars Insulin Sales by Type (2020-2025) & (K Units)

Table 44. APAC Biosimilars Insulin Sales by Application (2020-2025) & (K Units)

Table 45. Europe Biosimilars Insulin Sales by Country (2020-2025) & (K Units)

Table 46. Europe Biosimilars Insulin Revenue by Country (2020-2025) & (\$ millions)

Table 47. Europe Biosimilars Insulin Sales by Type (2020-2025) & (K Units)

Table 48. Europe Biosimilars Insulin Sales by Application (2020-2025) & (K Units)

Table 49. Middle East & Africa Biosimilars Insulin Sales by Country (2020-2025) & (K Units)

Table 50. Middle East & Africa Biosimilars Insulin Revenue Market Share by Country (2020-2025)

Table 51. Middle East & Africa Biosimilars Insulin Sales by Type (2020-2025) & (K Units)

Table 52. Middle East & Africa Biosimilars Insulin Sales by Application (2020-2025) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Biosimilars Insulin

Table 54. Key Market Challenges & Risks of Biosimilars Insulin

Table 55. Key Industry Trends of Biosimilars Insulin

Table 56. Biosimilars Insulin Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Biosimilars Insulin Distributors List

Table 59. Biosimilars Insulin Customer List

Table 60. Global Biosimilars Insulin Sales Forecast by Region (2026-2031) & (K Units)

Table 61. Global Biosimilars Insulin Revenue Forecast by Region (2026-2031) & (\$

millions)

Table 62. Americas Biosimilars Insulin Sales Forecast by Country (2026-2031) & (K Units)

Table 63. Americas Biosimilars Insulin Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 64. APAC Biosimilars Insulin Sales Forecast by Region (2026-2031) & (K Units)

Table 65. APAC Biosimilars Insulin Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 66. Europe Biosimilars Insulin Sales Forecast by Country (2026-2031) & (K Units)

Table 67. Europe Biosimilars Insulin Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 68. Middle East & Africa Biosimilars Insulin Sales Forecast by Country (2026-2031) & (K Units)

Table 69. Middle East & Africa Biosimilars Insulin Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 70. Global Biosimilars Insulin Sales Forecast by Type (2026-2031) & (K Units)

Table 71. Global Biosimilars Insulin Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 72. Global Biosimilars Insulin Sales Forecast by Application (2026-2031) & (K Units)

Table 73. Global Biosimilars Insulin Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 74. Eli Lilly Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 75. Eli Lilly Biosimilars Insulin Product Portfolios and Specifications

Table 76. Eli Lilly Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 77. Eli Lilly Main Business

Table 78. Eli Lilly Latest Developments

Table 79. Boehringer Ingelheim Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 80. Boehringer Ingelheim Biosimilars Insulin Product Portfolios and Specifications

Table 81. Boehringer Ingelheim Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 82. Boehringer Ingelheim Main Business

Table 83. Boehringer Ingelheim Latest Developments

Table 84. Biocon/Mylan Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 85. Biocon/Mylan Biosimilars Insulin Product Portfolios and Specifications

Table 86. Biocon/Mylan Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 87. Biocon/Mylan Main Business

Table 88. Biocon/Mylan Latest Developments

Table 89. Gan & Lee Pharmaceuticals Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 90. Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolios and Specifications

Table 91. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 92. Gan & Lee Pharmaceuticals Main Business

Table 93. Gan & Lee Pharmaceuticals Latest Developments

Table 94. Tonghua Dongbao Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 95. Tonghua Dongbao Biosimilars Insulin Product Portfolios and Specifications

Table 96. Tonghua Dongbao Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 97. Tonghua Dongbao Main Business

Table 98. Tonghua Dongbao Latest Developments

Table 99. United Laboratories Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 100. United Laboratories Biosimilars Insulin Product Portfolios and Specifications

Table 101. United Laboratories Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 102. United Laboratories Main Business

Table 103. United Laboratories Latest Developments

Table 104. Sanofi Basic Information, Biosimilars Insulin Manufacturing Base, Sales Area and Its Competitors

Table 105. Sanofi Biosimilars Insulin Product Portfolios and Specifications

Table 106. Sanofi Biosimilars Insulin Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 107. Sanofi Main Business

Table 108. Sanofi Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Biosimilars Insulin
- Figure 2. Biosimilars Insulin Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Biosimilars Insulin Sales Growth Rate 2020-2031 (K Units)
- Figure 7. Global Biosimilars Insulin Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Biosimilars Insulin Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Biosimilars Insulin Sales Market Share by Country/Region (2024)
- Figure 10. Biosimilars Insulin Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of Insulin Glargine
- Figure 12. Product Picture of Insulin Aspart
- Figure 13. Product Picture of Insulin Lispro
- Figure 14. Product Picture of Other
- Figure 15. Global Biosimilars Insulin Sales Market Share by Type in 2025
- Figure 16. Global Biosimilars Insulin Revenue Market Share by Type (2020-2025)
- Figure 17. Biosimilars Insulin Consumed in Type I Diabetes
- Figure 18. Global Biosimilars Insulin Market: Type I Diabetes (2020-2025) & (K Units)
- Figure 19. Biosimilars Insulin Consumed in Type II Diabetes
- Figure 20. Global Biosimilars Insulin Market: Type II Diabetes (2020-2025) & (K Units)
- Figure 21. Global Biosimilars Insulin Sale Market Share by Application (2024)
- Figure 22. Global Biosimilars Insulin Revenue Market Share by Application in 2025
- Figure 23. Biosimilars Insulin Sales by Company in 2025 (K Units)
- Figure 24. Global Biosimilars Insulin Sales Market Share by Company in 2025
- Figure 25. Biosimilars Insulin Revenue by Company in 2025 (\$ millions)
- Figure 26. Global Biosimilars Insulin Revenue Market Share by Company in 2025
- Figure 27. Global Biosimilars Insulin Sales Market Share by Geographic Region (2020-2025)
- Figure 28. Global Biosimilars Insulin Revenue Market Share by Geographic Region in 2025
- Figure 29. Americas Biosimilars Insulin Sales 2020-2025 (K Units)
- Figure 30. Americas Biosimilars Insulin Revenue 2020-2025 (\$ millions)
- Figure 31. APAC Biosimilars Insulin Sales 2020-2025 (K Units)

- Figure 32. APAC Biosimilars Insulin Revenue 2020-2025 (\$ millions)
- Figure 33. Europe Biosimilars Insulin Sales 2020-2025 (K Units)
- Figure 34. Europe Biosimilars Insulin Revenue 2020-2025 (\$ millions)
- Figure 35. Middle East & Africa Biosimilars Insulin Sales 2020-2025 (K Units)
- Figure 36. Middle East & Africa Biosimilars Insulin Revenue 2020-2025 (\$ millions)
- Figure 37. Americas Biosimilars Insulin Sales Market Share by Country in 2025
- Figure 38. Americas Biosimilars Insulin Revenue Market Share by Country (2020-2025)
- Figure 39. Americas Biosimilars Insulin Sales Market Share by Type (2020-2025)
- Figure 40. Americas Biosimilars Insulin Sales Market Share by Application (2020-2025)
- Figure 41. United States Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 42. Canada Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 43. Mexico Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 44. Brazil Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 45. APAC Biosimilars Insulin Sales Market Share by Region in 2025
- Figure 46. APAC Biosimilars Insulin Revenue Market Share by Region (2020-2025)
- Figure 47. APAC Biosimilars Insulin Sales Market Share by Type (2020-2025)
- Figure 48. APAC Biosimilars Insulin Sales Market Share by Application (2020-2025)
- Figure 49. China Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 50. Japan Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 51. South Korea Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 52. Southeast Asia Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 53. India Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 54. Australia Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 55. China Taiwan Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 56. Europe Biosimilars Insulin Sales Market Share by Country in 2025
- Figure 57. Europe Biosimilars Insulin Revenue Market Share by Country (2020-2025)
- Figure 58. Europe Biosimilars Insulin Sales Market Share by Type (2020-2025)
- Figure 59. Europe Biosimilars Insulin Sales Market Share by Application (2020-2025)
- Figure 60. Germany Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 61. France Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 62. UK Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 63. Italy Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 64. Russia Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 65. Middle East & Africa Biosimilars Insulin Sales Market Share by Country (2020-2025)
- Figure 66. Middle East & Africa Biosimilars Insulin Sales Market Share by Type (2020-2025)
- Figure 67. Middle East & Africa Biosimilars Insulin Sales Market Share by Application (2020-2025)

- Figure 68. Egypt Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 69. South Africa Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 70. Israel Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 71. Turkey Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 72. GCC Countries Biosimilars Insulin Revenue Growth 2020-2025 (\$ millions)
- Figure 73. Manufacturing Cost Structure Analysis of Biosimilars Insulin in 2025
- Figure 74. Manufacturing Process Analysis of Biosimilars Insulin
- Figure 75. Industry Chain Structure of Biosimilars Insulin
- Figure 76. Channels of Distribution
- Figure 77. Global Biosimilars Insulin Sales Market Forecast by Region (2026-2031)
- Figure 78. Global Biosimilars Insulin Revenue Market Share Forecast by Region (2026-2031)
- Figure 79. Global Biosimilars Insulin Sales Market Share Forecast by Type (2026-2031)
- Figure 80. Global Biosimilars Insulin Revenue Market Share Forecast by Type (2026-2031)
- Figure 81. Global Biosimilars Insulin Sales Market Share Forecast by Application (2026-2031)
- Figure 82. Global Biosimilars Insulin Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global Biosimilars Insulin Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/GE22CC326CBEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE22CC326CBEEN.html>